SS
CLDI icon

SBI Securities’s Calidi Biotherapeutics CLDI Stock Holding History

SBI Securities’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27 Buy
115
+69
+150% +$52 ﹤0.01% 3700
2025
Q4 		$54 Hold
46
– – ﹤0.01% 3561
2025
Q3 		$70 Sell
46
-1
-2% -$4 ﹤0.01% 3620
2025
Q2 		$129 Buy
47
+22
+88% +$107 ﹤0.01% 3453
2025
Q1 		$170 Buy
+25
New +$285 ﹤0.01% 3275

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SBI Securities's CLDI Position: Q1 2026 in Review

SBI Securities increased its Calidi Biotherapeutics (CLDI) stake by 150% in Q1 2026, buying an estimated $52 and bringing the position to 115 shares worth $27. The position accounts for ﹤0.01% of the portfolio, ranked #3700.

SBI Securities first reported a position in CLDI in Q1 2025 and has held it in 5 quarters since. The position peaked at $170 in Q1 2025. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • SBI Securities held 115 shares of Calidi Biotherapeutics worth $27 as of Q1 2026.
  • SBI Securities bought 69 Calidi Biotherapeutics shares in Q1 2026, an estimated $52.
  • Calidi Biotherapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #3700 holding.
  • SBI Securities first reported a position in Calidi Biotherapeutics in Q1 2025 and has held it in 5 quarters since.
  • SBI Securities's Calidi Biotherapeutics position peaked at $170 in Q1 2025.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.